Fresh Tracks Therapeutics, Inc. (FRTX)
For informational purposes only. Not financial advice. Analysis by Sedat Aydin, Founder & Editor-in-Chief | AI-powered analysis. Data sourced from SEC filings and institutional-grade financial providers. Editorially reviewed. Not financial advice.
Fresh Tracks Therapeutics, Inc. (FRTX) with AI Score 54/100 (Hold). Fresh Tracks Therapeutics, Inc. is a clinical-stage pharmaceutical company focused on developing prescription therapeutics for autoimmune, inflammatory, and other debilitating diseases. Market cap: 0, Sector: Healthcare.
Last analyzed: Mar 15, 2026Fresh Tracks Therapeutics, Inc. (FRTX) Healthcare & Pipeline Overview
Fresh Tracks Therapeutics, Inc. is a clinical-stage biopharmaceutical company specializing in the development of novel therapies for autoimmune and inflammatory diseases, with a focus on innovative treatments like sofpironium bromide and DYRK1A inhibitors, operating within the competitive biotechnology sector and targeting unmet medical needs.
Investment Thesis
Fresh Tracks Therapeutics presents a high-risk, high-reward investment profile typical of clinical-stage biotechnology companies. The company's value is primarily tied to the successful development and commercialization of its pipeline assets, particularly sofpironium bromide and BBI-02. Positive clinical trial results and regulatory approvals are key catalysts. The company's small market capitalization of $0.01 billion reflects the inherent uncertainty and risk associated with its early stage of development. The negative P/E ratio of -0.97 and a profit margin of -71.1% underscore the company's current lack of profitability. Investment hinges on the potential for future revenue generation from its therapeutic candidates. Upcoming clinical trial data for BBI-02 and BBI-10 will be critical in determining the company's future prospects. The company's collaborations with Carna Biosciences, Voronoi Inc., and others could provide additional value and expertise.
Based on FMP financials and quantitative analysis
Key Highlights
- Market capitalization of $0.01 billion, reflecting its status as a micro-cap company.
- Negative P/E ratio of -0.97, indicating current lack of profitability.
- Gross margin of 100.0%, potentially misleading due to limited revenue generation at this stage.
- Beta of 1.17, suggesting slightly higher volatility compared to the overall market.
- Sofpironium bromide has completed Phase III clinical trials for primary axillary hyperhidrosis, representing a near-term potential value driver.
Competitors & Peers
Strengths
- Pipeline of clinical-stage assets targeting unmet medical needs.
- Proprietary drug formulations and technologies.
- Collaboration agreements with research institutions and other companies.
- Focus on autoimmune and inflammatory diseases, a large and growing market.
Weaknesses
- Limited financial resources and reliance on external funding.
- High risk of clinical trial failures and regulatory setbacks.
- Small market capitalization and limited trading volume.
- Dependence on a small number of key assets.
Catalysts
- Clinical trial results for BBI-02 in autoimmune and inflammatory diseases.
- Clinical trial results for BBI-10 in autoinflammatory and rare genetic diseases.
- Potential regulatory approval of sofpironium bromide for primary axillary hyperhidrosis.
- Progress in securing strategic partnerships and collaborations.
- Advancement of next-generation kinase inhibitors.
Risks
- Clinical trial failures and regulatory setbacks.
- Competition from established pharmaceutical companies and other biotech firms.
- Patent expiration and generic competition.
- Limited financial resources and reliance on external funding.
- Changes in regulatory landscape and reimbursement policies.
Growth Opportunities
- Expansion into new therapeutic areas: Fresh Tracks Therapeutics can leverage its expertise in autoimmune and inflammatory diseases to expand its pipeline into related therapeutic areas, such as dermatology or rheumatology. The global dermatology market is projected to reach $45 billion by 2026, offering significant growth potential. This expansion could diversify the company's risk profile and create new revenue streams. Success depends on identifying promising targets and developing effective therapies.
- Strategic partnerships and collaborations: Fresh Tracks Therapeutics can pursue strategic partnerships and collaborations with larger pharmaceutical companies to accelerate the development and commercialization of its product candidates. These partnerships can provide access to funding, expertise, and distribution networks. The pharmaceutical industry is increasingly reliant on collaborations to drive innovation and growth. Securing a major partnership could significantly enhance the company's value and prospects.
- Advancement of BBI-02 and BBI-10: The successful development and commercialization of BBI-02 and BBI-10 represent significant growth opportunities for Fresh Tracks Therapeutics. These programs target autoimmune, inflammatory, and rare genetic diseases, addressing unmet medical needs. Positive clinical trial results and regulatory approvals could drive substantial revenue growth. The market for DYRK1A inhibitors and interferon gene stimulators is expected to grow rapidly in the coming years.
- Geographic expansion: Fresh Tracks Therapeutics can expand its geographic reach beyond the United States to target international markets. The global pharmaceutical market is highly fragmented, with significant opportunities in emerging markets. Expanding into Europe, Asia, or Latin America could drive revenue growth and increase the company's global presence. Success depends on navigating regulatory hurdles and establishing effective distribution networks.
- Acquisition of complementary assets: Fresh Tracks Therapeutics can pursue strategic acquisitions of complementary assets, such as other biotechnology companies or technologies, to expand its pipeline and capabilities. These acquisitions can provide access to new therapeutic areas, technologies, and expertise. The biotechnology industry is characterized by consolidation, with larger companies acquiring smaller, innovative firms. A successful acquisition could significantly enhance the company's value and prospects.
Opportunities
- Strategic partnerships and collaborations with larger pharmaceutical companies.
- Expansion into new therapeutic areas and geographic markets.
- Successful development and commercialization of pipeline assets.
- Acquisition of complementary assets to expand pipeline and capabilities.
Threats
- Competition from established pharmaceutical companies and other biotech firms.
- Patent expiration and generic competition.
- Changes in regulatory landscape and reimbursement policies.
- Economic downturn and reduced healthcare spending.
Competitive Advantages
- Proprietary drug formulations and technologies.
- Patent protection for developed therapeutics.
- Clinical trial data supporting efficacy and safety.
- Collaboration agreements with research institutions and other companies.
About FRTX
Fresh Tracks Therapeutics, Inc., established in 2009 and headquartered in Boulder, Colorado, is a clinical-stage pharmaceutical company dedicated to the development and commercialization of prescription therapeutics. The company focuses on addressing autoimmune, inflammatory, and other debilitating diseases. Originally known as Brickell Biotech, Inc., the company rebranded as Fresh Tracks Therapeutics in September 2022, signaling a strategic shift in its focus and pipeline. The company's lead product candidate is sofpironium bromide, which has completed Phase III clinical trials for the treatment of primary axillary hyperhidrosis, a condition characterized by excessive underarm sweating. Beyond sofpironium bromide, Fresh Tracks Therapeutics is also developing BBI-02, an oral DYRK1A inhibitor, for the treatment of autoimmune and inflammatory diseases. Additionally, the company is working on BBI-10, a covalent stimulator of interferon genes inhibitor, which holds potential for treating autoinflammatory and rare genetic diseases, as well as next-generation kinase inhibitors. These programs reflect the company's commitment to addressing a range of unmet medical needs in the autoimmune and inflammatory disease space. Fresh Tracks Therapeutics has established license and collaboration agreements with several companies, including Carna Biosciences, Inc., Voronoi Inc., Bodor Laboratories, Inc. and Dr. Nicholas S. Bodor, and AnGes, Inc., to support the development and commercialization of its product candidates.
What They Do
- Develops prescription therapeutics for autoimmune diseases.
- Focuses on treatments for inflammatory conditions.
- Targets other debilitating diseases.
- Develops sofpironium bromide for hyperhidrosis.
- Creates oral DYRK1A inhibitors like BBI-02.
- Develops covalent stimulators of interferon genes like BBI-10.
- Pursues next-generation kinase inhibitors.
Business Model
- Develops pharmaceutical products through research and development.
- Out-licenses or partners to commercialize developed products.
- Generates revenue through licensing agreements and potential product sales.
- Collaborates with other companies for research and development.
Industry Context
Fresh Tracks Therapeutics operates within the competitive biotechnology industry, which is characterized by high R&D costs, lengthy development timelines, and significant regulatory hurdles. The company focuses on the autoimmune and inflammatory disease market, a large and growing segment driven by increasing prevalence of these conditions and demand for novel therapies. The biotechnology industry is experiencing rapid innovation, with new technologies and treatment modalities emerging regularly. Competition includes established pharmaceutical companies and other biotech firms developing similar therapies. Success depends on clinical trial outcomes, regulatory approvals, and effective commercialization strategies.
Key Customers
- Patients suffering from autoimmune diseases.
- Patients with inflammatory conditions.
- Healthcare providers prescribing treatments.
- Pharmaceutical companies through licensing agreements.
FRTX Financials
FRTX Price Today & Live Chart
Fresh Tracks Therapeutics, Inc. (FRTX) stock price: Price data unavailable
FRTX Latest News
-
Stocks That Hit 52-Week Lows On Monday
benzinga · Apr 3, 2023
-
Stocks That Hit 52-Week Lows On Friday
benzinga · Mar 31, 2023
-
Stocks That Hit 52-Week Lows On Monday
benzinga · Mar 20, 2023
-
Stocks That Hit 52-Week Lows On Wednesday
benzinga · Dec 28, 2022
FRTX Analyst Consensus
Consensus Rating
Aggregated Buy/Hold/Sell recommendations from Benzinga, Yahoo Finance, and Finnhub for FRTX.
Price Targets
Wall Street price target analysis for FRTX.
FRTX MoonshotScore
What does this score mean?
The MoonshotScore rates FRTX's growth potential on a scale of 0-100 across multiple factors including innovation, market disruption, financial health, and momentum.
Competitors & Peers
Leadership: Albert Nicholas Marchio II
CEO
Albert Nicholas Marchio II serves as the CEO of Fresh Tracks Therapeutics, leading a small team of four employees. His background includes experience in the pharmaceutical and biotechnology industries, with a focus on corporate strategy, business development, and financial management. He has held leadership positions at various companies, contributing to strategic planning and execution. His expertise spans across drug development, commercialization, and investor relations.
Track Record: Under his leadership, Fresh Tracks Therapeutics has focused on advancing its pipeline of clinical-stage assets, including sofpironium bromide, BBI-02, and BBI-10. He has overseen the company's strategic shift towards autoimmune and inflammatory diseases. Key milestones include completing Phase III clinical trials for sofpironium bromide and establishing collaboration agreements with Carna Biosciences and Voronoi Inc.
Common Questions About FRTX (Healthcare)
What does Fresh Tracks Therapeutics, Inc. do?
Fresh Tracks Therapeutics, Inc. is a clinical-stage pharmaceutical company focused on developing and commercializing prescription therapeutics for autoimmune, inflammatory, and other debilitating diseases. The company's pipeline includes sofpironium bromide, which has completed Phase III clinical trials for primary axillary hyperhidrosis, as well as BBI-02, an oral DYRK1A inhibitor, and BBI-10, a covalent stimulator of interferon genes inhibitor. Fresh Tracks aims to address unmet medical needs in these therapeutic areas through innovative drug development and strategic collaborations.
What do analysts say about FRTX stock?
As of 2026-03-15, there is no available AI analysis for FRTX stock. Given its micro-cap status and clinical-stage nature, analyst coverage may be limited. Key valuation metrics to consider include the potential market size for its lead product candidates, the probability of success for its clinical trials, and the terms of its licensing and collaboration agreements. Investors should conduct their own due diligence and consider the inherent risks associated with investing in early-stage biotechnology companies.
What are the main risks for FRTX?
The main risks for Fresh Tracks Therapeutics include the inherent uncertainty of clinical trial outcomes, the potential for regulatory setbacks, competition from established pharmaceutical companies and other biotech firms, and the company's limited financial resources. Clinical trial failures or delays could significantly impact the company's value. Additionally, patent expiration and generic competition could erode future revenue streams. The company's reliance on external funding also poses a risk, as access to capital may be limited or diluted.
What are the key factors to evaluate for FRTX?
Fresh Tracks Therapeutics, Inc. (FRTX) currently holds an AI score of 54/100, indicating moderate score. Key strength: Pipeline of clinical-stage assets targeting unmet medical needs. Primary risk to monitor: Clinical trial failures and regulatory setbacks. This is not financial advice.
How frequently does FRTX data refresh on this page?
FRTX prices update in real time during U.S. market hours (9:30 AM-4:00 PM ET, weekdays). Fundamentals refresh after quarterly or annual filings. Analyst ratings and AI insights update daily. News is aggregated continuously from financial sources.
What has driven FRTX's recent stock price performance?
Recent price movement in Fresh Tracks Therapeutics, Inc. (FRTX) can be influenced by earnings results, analyst revisions, sector rotation, and broader market sentiment. Notable catalyst: Pipeline of clinical-stage assets targeting unmet medical needs. Check the News and Technical Analysis tabs for the latest drivers. Past performance does not predict future results.
Should investors consider FRTX overvalued or undervalued right now?
Determining whether Fresh Tracks Therapeutics, Inc. (FRTX) is overvalued or undervalued requires examining multiple metrics. Compare valuation ratios (P/E, P/S, EV/EBITDA) against sector peers for a comprehensive view.
What research should beginners do before buying FRTX?
Before investing in Fresh Tracks Therapeutics, Inc. (FRTX), research these four areas: (1) the company's revenue model and competitive position (see Company Overview), (2) financial health through revenue growth, margins, and cash flow (see MoonshotScore), (3) what Wall Street analysts recommend and their price targets (see Analyst tab), and (4) specific risk factors that could impact the stock (see Risk Factors section).
Disclaimer: This content is for informational purposes only and does not constitute investment advice. Always do your own research and consult a financial advisor.
Official Resources
Data provided for informational purposes only.
- Information is based on available data and may be subject to change.
- AI analysis is pending and may provide further insights.